Deep learning-driven discovery and optimization of natural LSD1 inhibitors for the treatment of Alzheimer's disease
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Zhonghua Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Chinese Medical Sciences; Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao; Henan Univers…. Hauptthemen laut MEDLINE: Alzheimer Disease, Histone Demethylases, Enzyme Inhibitors, Neuroprotective Agents. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Science and Technology Innovation Talents in Universities of Henan Province, Henan Province Natural Science Foundation, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder with limited effective disease-modifying treatments. Lysine-specific demethylase 1 (LSD1) has emerged as a promising target for AD therapy. However, current LSD1 inhibitors for AD still suffer from poor brain permeability, off-target toxicity, and chemical-scaffold scarcity. Herein, we developed a multimodal deep learning model (PLM-CAFT-DTA) for drug-target affinity (DTA) prediction. This model integrates ChemBERTa, ESM-2, graph attention, and cross-attention fusion to achieve high prediction precision. Using this model combined with virtual screening and molecular simulation, we identified silybin as a hit compound from a library of over 70,000 natural products. After rational modification, compound S3 was obtained with significantly improved LSD1 inhibition (IC₅₀ = 2.30 μM), approximately 7-fold more potent than the silybin. In vitro assays showed that S3 exhibited favorable neuroprotective and antioxidant activities. In APP/PS1 mice, S3 upregulated hippocampal H3K9me2, suppressed neuroinflammation and Aβ deposition, and improved cognitive function. By addressing unmet demands for AI-assisted anti-AD lead discovery, this study provides a generalized DTA tool for early-stage drug development, and identifies S3 as a novel LSD1 inhibitor with potent anti-AD efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academy of Chinese Medical Sciences; Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao; Henan University of Chinese Medicine, Zhengzhou 450046, China. Electronic address:…
- Academy of Chinese Medical Sciences; Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao; Henan University of Chinese Medicine, Zhengzhou 450046, China.
Förderung
- Science and Technology Innovation Talents in Universities of Henan Province
- Henan Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, Z., Sun, T., Han, M., Xiao, B., Liu, S., Zhang, J., Ma, J., Ma, H., Yang, J., & Zhang, Z. (2026). Deep learning-driven discovery and optimization of natural LSD1 inhibitors for the treatment of Alzheimer's disease. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110396
Vancouver
Li Z, Sun T, Han M, Xiao B, Liu S, Zhang J, et al. Deep learning-driven discovery and optimization of natural LSD1 inhibitors for the treatment of Alzheimer's disease. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110396
BibTeX
@article{Li2026,
author = {Li, Zhonghua and Sun, Tiancheng and Han, Mengyu and Xiao, Bingyu and Liu, Sijia and Zhang, Jiaxin and Ma, JinLian and Ma, Huifen and Yang, Jige and Zhang, Zhenqiang},
title = {Deep learning-driven discovery and optimization of natural LSD1 inhibitors for the treatment of Alzheimer's disease},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110396}
}
EUVIMED